Novo's oral Wegovy outsells Foundayo five to one in the first shared quarter
Oral Wegovy brought in about $496 million in the second quarter of 2026 versus $98 million for Lilly's pill Foundayo, an early sign of how the two obesity pills are competing on efficacy, convenience and price. [1]
Novo Nordisk's Wegovy pill outsold Eli Lilly's Foundayo by roughly five to one in the first full commercial quarter the two obesity pills shared. In the second quarter of 2026, oral Wegovy (semaglutide) generated DKK 3.22 billion, about $496 million, while Foundayo (orforglipron) recorded $98 million. [1]
Foundayo was approved by the FDA in April 2026, so the quarter was its first full one on the US market. [1] Oral Wegovy had a head start: its first quarter of sales came in at $355 million before rising to $496 million. [1] Novo's figure was slightly below the DKK 3.27 billion analysts had expected. [2]
Why Novo is ahead so far
Analysts interviewed by BioSpace pointed to two things. The first is brand carryover. Sadaf Javed of DelveInsight said Novo "extended the established Wegovy brand into an oral formulation, allowing it to leverage existing physician familiarity, patient awareness, and semaglutide experience rather than building a new obesity brand from scratch." [1] Sara Reci of GlobalData made a similar point, saying the name "Wegovy pill" is "immediately legible to patients and prescribers already familiar with the injectable." [1]
The second is efficacy. BioSpace reports oral Wegovy produces around 16.6% weight loss at 72 weeks versus 11.2% for Foundayo at the same time point, with no head-to-head trial comparing them directly. [1] Other published figures differ. A market tracker lists both orforglipron and oral semaglutide at roughly 15% weight loss, and cites Lilly's ATTAIN-1 trial as showing average weight loss of 12.4% at 72 weeks on the 36 mg dose of orforglipron, with 10.5% in ATTAIN-2 in people with type 2 diabetes alongside an average 1.8 percentage-point drop in HbA1c. [2] So the exact size of the gap depends on which numbers you use, and cross-trial comparisons are not the same as a direct test.
Novo's chief executive, Mike Doustdar, told Reuters on August 13 that the Wegovy pill currently holds about 90% of the US oral GLP-1 market. That figure is company-stated, was not published with an independent breakdown, and describes a market Lilly had only just entered. [2]
Where Lilly may push back
Foundayo has a simpler routine. Oral Wegovy must be taken with water, with no additional food or drink for at least 30 minutes; Foundayo carries no such restriction, which Javed called a "clear acceptability advantage" that "could further differentiate it as the oral market matures." [1]
Price is the other lever. Foundayo is a small molecule, which is easier and cheaper to make than oral semaglutide, a peptide. Truist analyst Srikripa Devarakonda said Foundayo is "a bigger [ex-U.S.] play" because Lilly can compete harder on price in more price-sensitive overseas markets, while in the US she expects Lilly to focus on marketing and access rather than lowering prices. [1]
Why it matters for patients
For people weighing a pill instead of a weekly shot, this quarter mostly describes market share, not medical superiority. Nothing here is a head-to-head trial. [1] But commercial momentum can shape real-world experience: which pill a pharmacy stocks, which one an insurer covers, how aggressively each company discounts, and how much education a prescriber has had about each option.
The daily routine differs in a way patients will notice. The 30-minute food-and-drink restriction on oral semaglutide is a real scheduling constraint that Foundayo does not have. [1] Price dynamics may also diverge, with analysts expecting small-molecule economics to give Lilly more room to discount, particularly outside the US. [1]
What happens next
Analysts do not expect Novo's lead to be permanent. Javed said Novo's early advantage "is unlikely to be permanent" as newer approaches arrive. [1] Lilly's triple agonist retatrutide showed 28.3% weight loss in the TRIUMPH-1 Phase 3 trial, with a BLA filing guided to the first quarter of 2027. [2] Novo's CagriSema, at about 22.7% weight loss, faces an FDA decision in the second half of 2026. [2]
Internationally, the UK authorized Foundayo on August 10, 2026, but NHS reimbursement requires a separate NICE appraisal that typically takes 12 to 18 months, so funded access there is unlikely before late 2027. [2]
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.